Company news
Zhejiang Huahai Pharmaceutical Co., Ltd. Class A (SSE:600521) news
Zhejiang Huahai Pharmaceutical Co., Ltd. Class A news releases on 6ix. Latest, Sep 30, 2026: "ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement…
Press releases & updates
"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on Progress in Providing Guarantee for Subsidiary
September 29, 2026
"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Third Indicative Announcement on Redemption at Maturity and Delisting of "HUAHAI Convertible Bonds"
September 24, 2026
"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Second Indicative Announcement on Maturity Redemption and Delisting of "HUAHAI Convertible Bonds"
September 23, 2026
"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."First Indicative Announcement on Maturity Redemption and Delisting of "HUAHAI Convertible Bonds"
September 22, 2026
"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on Convening the 2026 Semi-annual Performance Briefing
September 18, 2026
"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on Obtaining Overseas Marketing Authorization for the Formulation Products
September 14, 2026
"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on Pledge of Certain Shares Held by the Shareholder
September 10, 2026
Hansoh Pharmaceutical : BIOLOGICS LICENSE APPLICATION OF RISVUTATUG REZETCAN (HS-20093) FOR INJECTION FOR SMALL CELL LUNG CANCER ACCEPTED BY THE NMPA
September 7, 2026
"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Semi-annual Report for 2026
August 26, 2026
"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on Subsidiary Passing the Drug GMP Compliance Inspection
August 19, 2026
"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on the Proposed Selection of the Company's Products in the 12th Batch of National Centralized Drug Procurement
August 2, 2026
"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on the Signing of the Four-Party Supervision Agreement for Raised Funds
July 29, 2026
"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on Obtaining Approval for Drug Clinical Trials by Subsidiary
July 24, 2026
"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on Appointment of Senior Management
July 15, 2026
"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on Progress of Authorized Disposal of Financial Assets at an Appropriate Time
July 13, 2026
"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on Inclusion of the Company's Products in the National Essential Medicines List
July 10, 2026
"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on the Receipt of U.S. Customs Duty Refund
July 8, 2026
"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on Expected Increase in Semi-annual Performance for 2026
July 5, 2026
"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on Obtaining Drug Registration Certificate
July 2, 2026
"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on Conversion Result of Convertible Bonds and Share Changes
July 1, 2026
Announcement on Progress in Providing Guarantee for Holding Subsidiary
June 29, 2026
Announcement on Resolutions of the 13th Extraordinary Meeting of the 9th Board of Directors
June 26, 2026
Indicative Announcement on Acceptance of the Subsidiary’s Application for Marketing Authorization of Drugs
June 25, 2026
Announcement on Progress in Arbitration Case Involving the Company
June 23, 2026
Announcement on Obtaining Drug Registration Certificate by the Company and Its Subsidiaries
June 15, 2026
Announcement on Progress in Transfer of Equity in Subsidiary Huahai Tianheng (Shanghai) Pharmaceutical Research Co., Ltd.
June 12, 2026
Announcement on Implementation of Dividend Distribution for 2025
June 11, 2026
Announcement on Obtaining Drug Registration Certificate
June 8, 2026
Indicative Announcement on Suspending Conversion of "Huahai Convertible Bonds" When Implementing Dividend Distribution for 2025
June 5, 2026
Announcement on Release of Pledge and Re-pledge of Some Shares of Shareholders
June 4, 2026
Announcement on Obtaining Approval for Drug Clinical Trials by Subsidiary
June 2, 2026
Announcement on Convening Performance Briefing for 2025 and Q1 2026
May 26, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
May 21, 2026
Announcement on Cancellation of Account for Raised Funds
May 20, 2026
Indicative Announcement on Convening the 2025 Annual General Meeting
May 14, 2026
Announcement on Outline of Open Day for Investors
May 11, 2026
Announcement on Changing Independent Directors and Adjusting Members of Special Committees of Board of Directors
April 29, 2026
Announcement on Disclosure of the 2025 Annual Report by the Holding Subsidiary, Changxing Pharmaceutical Co., Ltd.
April 28, 2026
Announcement on the Return of Raised Funds
April 24, 2026
Announcement on Holding Open Day Activities for Investor
April 21, 2026
Announcement on Resolutions of the 10th Extraordinary Meeting of the 9th Board of Directors
April 17, 2026
Earnings Preannouncement for Q1 2026
April 14, 2026
Indicative Announcement on Expected Trigger of Downward Revision for the Conversion Price of ""Huahai Convertible Bonds"
April 10, 2026
Announcement on Conversion Result of Convertible Corporate Bonds and Share Changes
April 1, 2026
Announcement on Resolutions of the 9th Extraordinary Meeting of the 9th Board of Directors
March 27, 2026
Announcement on Resolutions of the 8th Extraordinary Meeting of the 9th Board of Directors
March 20, 2026
Announcement on Maturity of Partial Idle Raised Funds Used for Cash Management
March 19, 2026
Announcement on Subsidiary HB0025 Injection Initiating Endometrial Cancer Phase III Clinical Trial
March 18, 2026
Announcement on Obtaining the U.S. FDA Approval for the Product Gabapentin Capsules
March 10, 2026
Announcement on Obtaining Drug Registration Certificate by Subsidiary
March 9, 2026